{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:01:12Z","timestamp":1792425672252,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Mast cell leukemia represents the most malignant subtype of systemic mastocytosis, characterized by a dire clinical prognosis. Currently, no standard treatment regimen exists, with allogeneic hematopoietic stem cell transplantation being the sole option that may extend patient survival. Most mastocytosis patients exhibit mutations in the KIT gene. This paper presents a case of mast cell leukemia manifesting primarily as intractable shock and extensive bone destruction. Notably, the patient tested negative for KIT gene mutations but exhibited an FGFR1 gene rearrangement. Initial treatment with venetoclax and azacitidine proved ineffective, prompting a shift to second-line targeted therapy using an FGFR1 inhibitor. This case is the first to report FGFR1 gene rearrangement in a mast cell leukemia patient, offering deeper molecular insights into this highly aggressive disease.<\/jats:p>","DOI":"10.3389\/fonc.2026.1830652","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:57:15Z","timestamp":1778129835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Experience of a rare case of primary acute mast cell leukemia with FGFR1 gene rearrangement"],"prefix":"10.3389","volume":"16","author":[{"given":"Yalu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Laboratory, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Pathology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/dc.23965","article-title":"Acute mast cell leukemia: A rare but highly aggressive hematopoietic neoplasm","volume":"46","author":"Costopoulos","year":"2018","journal-title":"Diagn Cytopathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.163964","article-title":"The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm","volume":"102","author":"Jawhar","year":"2017","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.05.018","article-title":"Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome","volume":"59","author":"Jain","year":"2017","journal-title":"Leuk Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008292","article-title":"Mast cell leukemia: Clinical and molecular features and survival outcomes of patients in the ECNM registry","volume":"7","author":"Kennedy","year":"2023","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000504099","article-title":"The spectrum of aggressive mastocytosis: A workshop report and literature review","volume":"87","author":"Leguit","year":"2020","journal-title":"Pathobiology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v126.23.828.828","article-title":"ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis","volume":"175","author":"Pardanani","year":"2016","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-004-4189-6","article-title":"Signal transduction via the stem cell factor receptor\/c-Kit","volume":"61","author":"Ronnstrand","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.6087","article-title":"The C-kit receptor-mediated signal transduction and tumor-related diseases","volume":"9","author":"Liang","year":"2013","journal-title":"Int J Biol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.5.1365","article-title":"Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant","volume":"98","author":"Chian","year":"2001","journal-title":"Blood"},{"key":"B20","article-title":"D816V mutation of KIT specifically induces phosphorylation of HNRNPL and HNRNPK in COS-1 cells","volume":"39","author":"Zhang","year":"2023","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02186-x","article-title":"Allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: A retrospective analysis of the DRST and GREM registries","volume":"38","author":"Lubke","year":"2024","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1182\/blood.2021012168","article-title":"Myeloid\/lymphoid neoplasm with FGFR1 rearrangement","volume":"138","author":"Germans","year":"2021","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.60.1157","article-title":"The 8p11 myeloproliferative syndrome: A review of recent literature","volume":"60","author":"Kirito","year":"2019","journal-title":"Rinsho Ketsueki"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: A review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-021-01460-1","article-title":"IRAK1-regulated IFN-gamma signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological Malignancies","volume":"20","author":"Cai","year":"2021","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.10.019","article-title":"FGFR1 translocation with concurrent myeloproliferative neoplasm, systemic mastocytosis, and lymphoblastic lymphoma: A case report","volume":"74","author":"Chang","year":"2018","journal-title":"Hum Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27026","article-title":"Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma\/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement","volume":"98","author":"Loscocco","year":"2023","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/bf00118411","article-title":"Tissue dosimetry, physiologically-based pharmacokinetic modeling, and cancer risk assessment","volume":"5","author":"Andersen","year":"1989","journal-title":"Cell Biol Toxicol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.147863","article-title":"A case with ZNF198-FGFR1 gene rearrangement presenting as acute eosinophil myeloid leukemia","volume":"128","author":"Chao","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2500017","article-title":"Pemigatinib for myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"4","author":"Verstovsek","year":"2025","journal-title":"NEJM Evid"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2894","article-title":"Identification of functional cooperative mutations of SETD2 in human acute leukemia","volume":"46","author":"Zhu","year":"2014","journal-title":"Nat Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18811","article-title":"New insights into the clinical characteristics of SETD2-mutated acute myeloid leukaemia","volume":"202","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3751","article-title":"Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance","volume":"21","author":"Yoda","year":"2015","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.210","article-title":"An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia","volume":"36","author":"Zimmermannova","year":"2017","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.196931","article-title":"Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia","volume":"104","author":"Gimenez","year":"2019","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1830652\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:57:19Z","timestamp":1778129839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1830652\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1830652"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1830652","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"article-number":"1830652"}}